关于西格玛-1受体激动剂氟伏沙明治疗多发性硬化症的观点。
Viewpoints Sigma-1 receptor agonist fluvoxamine for multiple sclerosis.
作者信息
Hashimoto Kenji
机构信息
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, 1-8-1 Inohana, Chiba, 260-8670, Japan.
出版信息
Brain Behav Immun Health. 2024 Mar 13;37:100752. doi: 10.1016/j.bbih.2024.100752. eCollection 2024 May.
Accumulating evidence suggests that the Epstein-Barr virus (EBV) plays a key role in the development of multiple sclerosis (MS). Additionally, depressive symptoms often precede the onset of MS. Given the role of the XBP1-sigma-1 receptor complex in the endoplasmic reticulum during EBV reactivation, the author proposes that fluvoxamine, an antidepressant with sigma-1 receptor agonism, could be a suitable therapeutic drug for MS.
越来越多的证据表明，爱泼斯坦-巴尔病毒（EBV）在多发性硬化症（MS）的发展中起关键作用。此外，抑郁症状通常在MS发病之前出现。鉴于XBP1-σ1受体复合物在内质网中EBV重新激活过程中的作用，作者提出，氟伏沙明这种具有σ1受体激动作用的抗抑郁药可能是一种适用于MS的治疗药物。
Zotero 插件